All Articles tagged castration-resistant prostate cancer

• Oncology
  August 19, 2024 EDT
  Real-World Clinical Outcomes and Treatment Patterns Among Black and Non-Black Patients With Prostate Cancer Initiated on Apalutamide in a Urology Setting
  Benjamin H. LowentrittCarmine RossiErik MuserFrederic KinkeadBronwyn MoorePatrick LefebvreDominic PilonShawn Du

  This study describes real-world treatment patterns and clinical outcomes among patients with mCSPC or nmCRPC who initiated apalutamide in the United States.

  Abstract
• Oncology
  October 31, 2023 EDT
  Central Nervous System-related Conditions and Associated Healthcare Resource Use Among Japanese nmCRPC Patients Based on Retrospective Claims Data
  Dianne A. LedesmaJonathan L. ChuaSusan S.H. TangXiu W. Lim

  We described CNS-related concomitant conditions during ADT and/or AA treatment and the subsequent healthcare resource utilization in Japanese nonmetastatic castration-resistant prostate cancer patients.

  Abstract
• Oncology
  January 29, 2018 EDT
  Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain
  Eva Tirado MercierDaniel Callejo VelascoMarta Rubio CabezasCristina Moretones AgutMeritxell Granell Villalón

  Cost-effectiveness analysis of radium-223 plus Best Supportive Care compared to BSC in the treatment of patients with metastatic castration-resistant prostate cancer and without previous docetaxel treatment.

  Abstract
• Oncology
  January 06, 2015 EDT
  Real-World Treatment Patterns in Men with Castration- Resistant Prostate Cancer Receiving Docetaxel
  Keith L. DavisBenjamin GutierrezTeresa ZyczynskiJames A. Kaye

  Docetaxel has been a standard of care for castration-resistant prostate cancer in the United States since 2004, yet little has been reported on its patterns of use in routine practice.

  Abstract